Kühne Wissenschaft zum Nutzen der Patienten

Einen Unterschied im Leben von Patienten auf der ganzen Welt bewirken.

At Celgene, bold science that benefits patients is at the core of our values and our business. Each year, Celgene’s cutting-edge medical research helps more patients around the world. While patients are the focus of our mission, we also take very seriously our responsibilities to our employees, our communities and our environment—responsibilities that we continue to live up to. Celgene’s 2018 Corporate Responsibility Report, released this week, highlights how we are working to make a difference in the lives of patients, communities and economies around the world.

“We are at a very important time in our company’s journey to help patients and create increased value for our stockholders,” Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation, said. “Over the next two years, we expect to advance five late-stage products toward regulatory approval. These therapies represent the promise of our industry-leading investments in research and the beginning of our next wave of innovation.”

Patients First

Celgene’s commitment to changing the course of human health includes helping patients living in developing parts of the world. In 2017, Celgene joined 24 biopharmaceutical companies in the Access Accelerated partnership to improve access to treatment and care for non-communicable diseases — such as cancer — in low- and middle-income countries.

2018 Corporate Responsibility Report

During its first year, the partnership moved toward its goal by advancing 62 programs, including the Celgene Cancer Care Links™ grant program1 and the Academic Model Providing Access to Healthcare (AMPATH) Oncology Partnership, which Celgene joined in 2011 to increase access to cancer diagnosis and treatment in Kenya.

Celgene introduced the Cancer Care Links™ in December 2017 to improve cancer care in resource-constrained countries by giving organizations with existing infrastructure an opportunity to apply for grants to support oncology training, cancer prevention and detection, nursing programs, general medical support, pharmacy programs, and awareness and education initiatives. The first grant recipients were announced in December 2018.

This past March, Access Accelerated hosted a forum in Kenya, where Zeba Khan, Ph.D., Vice President of Corporate Responsibility for Celgene, took part in a panel to discuss the AMPATH Oncology Partnership. “Our partnership with AMPATH works within the current healthcare system to address a local need and to improve multiple myeloma care in Kenya,” Khan said.

ENGAGING ACROSS SECTORS AND DISCIPLINES TO ADDRESS NCDs

THE “ENGAGING ACROSS SECTORS AND DISCIPLINES TO ADDRESS NCDs” PANEL INCLUDED PATIENTS, HEALTHCARE PROFESSIONALS, BIOPHARMACEUTICAL COMPANIES, NON-PROFIT ORGANIZATIONS AND KENYA’S MINISTRY OF HEALTH.

Supporting Communities and the Planet

At Celgene, we’re committed to making a positive impact on the communities where we work and live through giving and volunteerism, and to the health of the planet through environmental stewardship and resource conservation.

Last year, more than 2,000 Celgene employees ran, cycled or walked in races and events to support finding a cure for serious diseases, including blood cancers, pancreatic cancer, psoriasis and psoriatic arthritis. In 2017, more than 1,000 Celgene employees helped raise $700,000 to support the Leukemia & Lymphoma Society’s Light The Night® events, making Celgene its top biopharmaceutical fundraising partner. Celgene was also the first National Presenting Sponsor of PurpleStride®, the Walk to End Pancreatic Cancer, in 2017. More than 280 employees participated in 52 PurpleStride walks and runs, raising $57,000.

Meanwhile, Celgene is making strong progress to meeting our 2020 environmental goals, which focus on reducing our carbon footprint, investing more in renewable electricity, reducing water withdrawal and reducing waste generation. This year, Celgene expanded its portfolio of LEED®-certified buildings and continued our trend of purchasing renewable energy. Renewable sources now make up 50 percent of all power used by Celgene worldwide, and wind-powered electricity fuels 73 percent of U.S. facilities’ energy. This achievement has resulted in an invitation to join the U.S. Environmental Protection Agency’s Green Power Partnership.

Built on Integrity

Celgene’s business culture is built on integrity, ethics, sound decision-making and behaviors that reflect our values and focus on patients. This year, Celgene joined the Pharmaceutical Supply Chain Initiative (PSCI) to enhance sustainability within our supply chain and was recognized for excellence in responsible clinical trial data sharing in the Bioethics International Good Pharma Scorecard, ranking in the top five for Clinical Trial Transparency.

Whether it’s sharing clinical trial data or providing grants to organizations in resource-constrained countries to improve the cancer care infrastructure, the common thread that binds our employees and all our activities is our focus on putting patients first. “We remain steadfastly committed to our mission, as we work to discover, develop and deliver to patients new and even more effective ways to improve and extend the lives of patients around the world,” Alles said.

To learn more about Celgene’s Corporate Responsibility activities, read the 2018 Celgene Corporate Responsibility Report.